This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

J. M. Walshe, ScD
Department of Neurology The Middlesex Hospital London, W1N 8AA United Kingdom

Arch Neurol. 1992;49(2):132.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

—Brewer and his colleagues¹ report on the use of tetrathiomolybdate as an anticopper agent in the treatment of Wilson's disease, employing this compound as an initial therapy in an attempt to avoid the increase in symptoms sometimes seen after the use of chelating agents. While they refer to the important work of Mills and his associates at the Rowett Research Institute in Aberdeen, Scotland, where much work has been done on experimental animals, they seem unaware that the ability of thiomolybdates to induce copper deficiency in ruminants has been known since the 1940s as was described by Dick² in 1953. An attempt to use molybdate as an anticopper treatment for Wilson's disease was made in the 1950s³ without success. The reason for the failure of this study was that the thiosalt was not used and the molybdate and sulfate given to the patients was . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?